文献速递类风湿关节炎

地舒单抗对接受传统合成改善病情抗风湿药治疗的类风湿关节炎患者关节结构破坏的影响:DESIRABLE随机双盲安慰剂对照3期试验

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.
PubMed 文献 · Ann Rheum Dis · 2019-04-29

这项日本多中心随机双盲安慰剂对照3期研究纳入654例接受csDMARD的RA患者,比较地舒单抗60mg每3个月、每6个月与安慰剂对12个月mTSS变化的影响。结果显示地舒单抗组关节破坏进展显著减少,腰椎BMD显著升高,安全性与安慰剂无重大差异。

要点

  • 地舒单抗60mg每3个月或每6个月均显著抑制接受csDMARD的RA患者12个月mTSS进展。
  • 地舒单抗显著改善骨侵蚀评分并升高腰椎BMD,但对关节间隙狭窄评分无显著组间差异。
  • 地舒单抗安全性与安慰剂无重大差异。

核心结论

  • 在接受csDMARD治疗的RA患者中,地舒单抗可抑制关节破坏进展、提高BMD且耐受性良好。

研究设计与样本

  • 日本多中心、随机、双盲、平行组、安慰剂对照3期研究,纳入654例接受csDMARD且年龄≥20岁的RA患者,按1:1:1随机分配至地舒单抗60mg每3个月、每6个月或安慰剂组。

主要发现

  • 12个月mTSS平均变化:安慰剂组1.49(95%CI 0.99至1.99),Q6M组0.99(95%CI 0.49至1.49,p=0.0235),Q3M组0.72(95%CI 0.41至1.03,p=0.0055)。
  • 12个月骨侵蚀评分平均变化:安慰剂组0.98(95%CI 0.65至1.31),Q6M组0.51(95%CI 0.22至0.80,p=0.0104),Q3M组0.22(95%CI 0.09至0.34,p=0.0001)。
  • 关节间隙狭窄评分未见显著组间差异。
  • 腰椎(L1-L4)BMD百分比变化:安慰剂组-1.03%,Q6M组3.99%(p<0.0001),Q3M组4.88%(p<0.0001)。
  • 各组安全性特征未见重大差异。

关键数值与推荐

  • 12个月mTSS平均变化安慰剂组1.49(95%CI 0.99至1.99)、Q6M组0.99(95%CI 0.49至1.49,p=0.0235)、Q3M组0.72(95%CI 0.41至1.03,p=0.0055)。
  • 12个月骨侵蚀评分平均变化安慰剂组0.98(95%CI 0.65至1.31)、Q6M组0.51(95%CI 0.22至0.80,p=0.0104)、Q3M组0.22(95%CI 0.09至0.34,p=0.0001)。
  • 腰椎(L1-L4)BMD百分比变化安慰剂组-1.03%、Q6M组3.99%(p<0.0001)、Q3M组4.88%(p<0.0001)。

临床怎么用

  • 对接受csDMARD治疗且存在关节结构破坏风险的RA患者,地舒单抗60mg每3个月或每6个月可作为抑制结构破坏并改善BMD的联合治疗选择。

局限性

  • 研究在日本进行,结论外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA). METHODS: This was a multi-centre, randomised, double-blind, parallel-group, placebo-controlled phase 3 study in Japan. Patients with RA aged ≥20 years receiving csDMARDs were randomly assigned (1:1:1) to denosumab 60 mg every 3 months (Q3M), denosumab 60 mg every 6 months (Q6M) or placebo. The change in the modified total Sharp score (mTSS) and effect on bone mineral density (BMD) at 12 months was evaluated. RESULTS: In total, 654 patients received the trial drugs. Denosumab groups showed significantly less progression of joint destruction. The mean changes in the mTSS at 12 months were 1.49 (95% CI 0.99 to 1.99) in the placebo group, 0.99 (95% CI 0.49 to 1.49) in the Q6M group (p=0.0235) and 0.72 (95% CI 0.41 to 1.03) in the Q3M group (p=0.0055). The mean changes in bone erosion score were 0.98 (95% CI 0.65 to 1.31) in the placebo group, 0.51 (95% CI 0.22 to 0.80) in the Q6M group (p=0.0104) and 0.22 (95% CI 0.09 to 0.34) in the Q3M group (p=0.0001). No significant between-group difference was observed in the joint space narrowing score. The per cent change in lumbar spine (L1-L4) BMD in the placebo, Q6M and Q3M groups were -1.03%, 3.99% (p<0.0001) and 4.88% (p<0.0001). No major differences were observed among safety profiles. CONCLUSIONS: Denosumab inhibits the progression of joint destruction, increases BMD and is well tolerated in patients with RA taking csDMARD.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Takeuchi T, Tanaka Y, Soen S, et al. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. Ann Rheum Dis. 2019. PMID: 31036625. doi:10.1136/annrheumdis-2018-214827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。